These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 34424404)

  • 41. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
    Shen L; Xu JM; Feng FY; Jiao SC; Wang LW; Li J; Guan ZZ; Qin SK; Wang JJ; Yu SY; Wang YJ; Jin YN; Tao M; Zheng LZ; Pan LX
    Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):295-300. PubMed ID: 23985260
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.
    Hofheinz RD; Hegewisch-Becker S; Kunzmann V; Thuss-Patience P; Fuchs M; Homann N; Graeven U; Schulte N; Merx K; Pohl M; Held S; Keller R; Tannapfel A; Al-Batran SE
    Int J Cancer; 2021 Sep; 149(6):1322-1331. PubMed ID: 34019698
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
    Kimura Y; Fujii M; Masuishi T; Nishikawa K; Kunisaki C; Matsusaka S; Segawa Y; Nakamura M; Sasaki K; Nagao N; Hatachi Y; Yuasa Y; Asami S; Takeuchi M; Furukawa H; Nakajima T;
    Gastric Cancer; 2018 May; 21(3):421-427. PubMed ID: 28936560
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
    Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).
    Miura Y; Sukawa Y; Hironaka S; Mori M; Nishikawa K; Tokunaga S; Okuda H; Sakamoto T; Taku K; Nishikawa K; Moriwaki T; Negoro Y; Kimura Y; Uchino K; Shinozaki K; Shinozaki H; Musha N; Yoshiyama H; Tsuda T; Miyata Y; Sugimoto N; Shirakawa T; Ito M; Yonesaka K; Yoshimura K; Boku N; Nosho K; Takano T; Hyodo I
    Gastric Cancer; 2018 Jan; 21(1):84-95. PubMed ID: 28497176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [A Case of HER2-Positive Esophagogastric Junction Cancer with Perforation Curatively Resected after Neoadjuvant Chemotherapy plus Trastuzumab].
    Toshima H; Hisamatsu A; Shimada K; Saito M; Suzuki M; Matsukawa M; Inoue H
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):761-4. PubMed ID: 27306816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HER2 testing in gastric cancer: a practical approach.
    Rüschoff J; Hanna W; Bilous M; Hofmann M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
    Mod Pathol; 2012 May; 25(5):637-50. PubMed ID: 22222640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting HER2 in metastatic gastroesophageal adenocarcinomas: What is new?
    Coutzac C; Funk-Debleds P; Cattey-Javouhey A; Desseigne F; Guibert P; Marolleau P; Rochefort P; de la Fouchardière C
    Bull Cancer; 2023 May; 110(5):552-559. PubMed ID: 36229267
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.
    Mondaca S; Margolis M; Sanchez-Vega F; Jonsson P; Riches JC; Ku GY; Hechtman JF; Tuvy Y; Berger MF; Shah MA; Kelsen DP; Ilson DH; Yu K; Goldberg Z; Epstein AS; Desai A; Chung V; Chou JF; Capanu M; Solit DB; Schultz N; Janjigian YY
    Gastric Cancer; 2019 Mar; 22(2):355-362. PubMed ID: 30088161
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
    Rivera F; Romero C; Jimenez-Fonseca P; Izquierdo-Manuel M; Salud A; Martínez E; Jorge M; Arrazubi V; Méndez JC; García-Alfonso P; Reboredo M; Barriuso J; Muñoz-Unceta N; Jimeno R; López C
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1175-1181. PubMed ID: 30927036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma.
    Subasinghe D; Acott N; Kumarasinghe MP
    Gastrointest Endosc; 2019 Jul; 90(1):44-54. PubMed ID: 30928424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
    Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
    Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
    Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis.
    Ter Veer E; Creemers A; de Waal L; van Oijen MGH; van Laarhoven HWM
    Int J Cancer; 2018 Jul; 143(2):438-448. PubMed ID: 29451302
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
    Makiyama A; Sukawa Y; Kashiwada T; Kawada J; Hosokawa A; Horie Y; Tsuji A; Moriwaki T; Tanioka H; Shinozaki K; Uchino K; Yasui H; Tsukuda H; Nishikawa K; Ishida H; Yamanaka T; Yamazaki K; Hironaka S; Esaki T; Boku N; Hyodo I; Muro K
    J Clin Oncol; 2020 Jun; 38(17):1919-1927. PubMed ID: 32208960
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
    Gong J; Liu T; Fan Q; Bai L; Bi F; Qin S; Wang J; Xu N; Cheng Y; Bai Y; Liu W; Wang L; Shen L
    BMC Cancer; 2016 Feb; 16():68. PubMed ID: 26857702
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
    Palacio S; Loaiza-Bonilla A; Kittaneh M; Kyriakopoulos C; Ochoa RE; Escobar M; Arango B; Restrepo MH; Merchan JR; Rocha Lima CM; Hosein PJ
    Anticancer Res; 2014 Jan; 34(1):301-6. PubMed ID: 24403478
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Two cases of unresectable advanced gastric cancer treated with S-1, CDDP and trastuzumab].
    Ogino T; Kawamura M; Tsutsumi K; Sakamoto N; Kodama H; Machida T; Takahashi T; Takanashi S; Nakamura Y; Ishii R
    Gan To Kagaku Ryoho; 2013 Feb; 40(2):237-40. PubMed ID: 23411963
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Two cases of human epidermal growth factor receptor 2-positive advanced gastric cancer successfully treated with S-1, cisplatin, and trastuzumab combination therapy followed by curative resection].
    Yasuyama A; Mikata S; Soma Y; Yoshikawa Y; Watase C; Kubota M; Miyake Y; Matsuura Y; Kim HM; Murakami M; Hirota M; Morishima H; Matsunami N; Hasegawa J; Miwa H; Nezu R
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2203-6. PubMed ID: 24394060
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
    Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
    Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.